B-cell Depletion: Therapy & Mechanism
B-cell depletion refers to the targeted reduction or elimination of B-lymphocytes from the blood and tissues. It is used therapeutically in autoimmune diseases and certain blood cancers.
Things worth knowing about "B-cell depletion"
B-cell depletion refers to the targeted reduction or elimination of B-lymphocytes from the blood and tissues. It is used therapeutically in autoimmune diseases and certain blood cancers.
What is B-cell Depletion?
B-cell depletion is a medical process in which B-lymphocytes – a specific subset of white blood cells that are part of the immune system – are deliberately removed or significantly reduced from the blood, bone marrow, or other tissues. B-lymphocytes (also called B-cells) play a central role in the immune response by producing antibodies. In certain diseases where B-cells produce harmful autoantibodies or grow uncontrollably, their targeted elimination becomes therapeutically beneficial.
Mechanism of Action
B-cell depletion is primarily achieved using monoclonal antibodies that bind specifically to surface proteins on B-cells. The most common target molecule is CD20, a protein expressed on the surface of mature B-cells. When a CD20-directed antibody – such as rituximab – binds to this molecule, the B-cell is destroyed through several mechanisms:
- Antibody-dependent cell-mediated cytotoxicity (ADCC): Immune effector cells recognize the bound antibody and destroy the B-cell.
- Complement activation: The complement system is activated, leading to lysis of the B-cell.
- Direct induction of apoptosis: The antibody directly triggers programmed cell death in the B-cell.
In addition to CD20-directed antibodies, there are also agents that target other B-cell surface molecules such as CD19 or CD22.
Indications
Autoimmune Diseases
In autoimmune diseases, the immune system mistakenly produces antibodies against the body's own tissues. B-cell depletion can interrupt this process. Typical indications include:
- Rheumatoid arthritis (inflammatory joint disease)
- Multiple sclerosis (inflammatory disease of the nervous system)
- Systemic lupus erythematosus (SLE)
- ANCA-associated vasculitides (inflammatory blood vessel diseases)
- Neuromyelitis optica spectrum disorders (NMOSD)
Hematological Malignancies
In B-cell lymphomas and other B-cell neoplasms (malignant B-cell diseases), B-cell depletion is used as part of chemotherapy regimens or as a standalone treatment. Examples include:
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Chronic lymphocytic leukemia (CLL)
Key Medications for B-cell Depletion
The most well-known agents used for B-cell depletion include:
- Rituximab (anti-CD20; the first approved monoclonal antibody of this type)
- Obinutuzumab (second-generation anti-CD20)
- Ofatumumab (anti-CD20)
- Ocrelizumab (anti-CD20; approved for multiple sclerosis)
- Ublituximab (anti-CD20)
- Inebilizumab (anti-CD19)
Side Effects and Risks
Since B-cells are an essential component of the immune system, their depletion leads to a temporary weakening of immune defenses. Possible side effects include:
- Increased susceptibility to infections, particularly bacterial and viral
- Infusion-related reactions (fever, chills, blood pressure drops) with intravenous administration
- Reactivation of latent infections (e.g., hepatitis B, tuberculosis)
- Hypogammaglobulinemia (low antibody levels in the blood) with long-term therapy
- Progressive multifocal leukoencephalopathy (PML) (a rare but serious brain infection)
Before initiating B-cell depletion therapy, screening for latent infections is typically performed and the vaccination status of the patient is reviewed.
Monitoring and Follow-up
Following B-cell depletion therapy, the number of B-cells in the blood is regularly monitored (using flow cytometry), along with immunoglobulin levels. B-cell recovery typically begins after 6–12 months, but may vary depending on the agent used and the individual response of the patient.
References
- Pescovitz MD. - Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. American Journal of Transplantation, 2006.
- Hauser SL et al. - Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017.
- Smolen JS et al. - EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Verwandte Produkte
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.